Program
epetraborole
Also written as “Epetraborole”, “GSK2251052” and “AN3365”.
Its studies are mostly in Community-Acquired Infections · Polycythemia Vera · Respiratory Tract Infections · Renal Insufficiency · Gram-Negative Bacterial Infections, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 70 open or running | phase 2since Jun 9, 2011 | Dec 16, 2010 | none ahead |
| AN2 Therapeutics | 51 open or running | phase 3since Mar 24, 2022 | May 11, 2021 | Apr 2029phase 2 · NCT07891533 |
| Pfizer | 10 open or running | phase 1since Oct 20, 2009 | Oct 20, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 20, 2009First study: phase 1 study in Gram-Negative Bacterial InfectionsNew to PfizerPfizer · NCT01015014 · 64 enrolled · Australia
- Dec 16, 2010GlaxoSmithKline's first studies: 2 phase 1 studiesNew to GlaxoSmithKlineGlaxoSmithKline · NCT01267968, NCT01262885
- Jun 9, 20112 phase 2 studiesGlaxoSmithKline · NCT01381562, NCT01381549
- Nov 17, 2011Phase 1 study in Community-Acquired InfectionsGlaxoSmithKline · NCT01475695 · 6 enrolled · Netherlands
- Dec 15, 2011Phase 1 study in Community-Acquired InfectionsGlaxoSmithKline · NCT01495065 · 8 enrolled · United States
- Sep 20, 2012Phase 1 study in Community-Acquired InfectionsGlaxoSmithKline · NCT01702350 · 24 enrolled · Australia
- May 11, 2021AN2 Therapeutics's first study: phase 1 study in Healthy VolunteersNew to AN2 TherapeuticsAN2 Therapeutics · NCT04892641 · 51 enrolled · Australia
- Feb 17, 2022Phase 1 study in Renal InsufficiencyAN2 Therapeutics · NCT05283746 · 40 enrolled · United States
- Mar 24, 2022Phase 3 study in Respiratory Tract InfectionsAN2 Therapeutics · NCT05327803 · 177 enrolled · United States, Australia, Japan and more
- Jun 27, 2023Phase 1 study in Healthy VolunteersAN2 Therapeutics · NCT05995444 · 24 enrolled · United States
- Oct 17, 2026Phase 2 study in Polycythemia VeraAN2 Therapeutics · NCT07891533 · 75 planned · Australia
Ahead
- Apr 2029Primary completion: phase 2 study in Polycythemia VeraAN2 Therapeutics · NCT07891533
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Leucine--tRNA ligase inhibitor”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07891533Polycythemia Vera · Australia | 2 | Not yet recruiting | AN2 Therapeutics | Apr 2029 | 75 |
| NCT05995444Healthy Volunteers · United States | 1 | Completed | AN2 Therapeutics | Jul 26, 2023 | 24 |
| NCT05327803Respiratory Tract Infections · United States, Australia, Japan and more | 3 | Terminated | AN2 Therapeutics | Dec 18, 2024 | 177 |
| NCT05283746Renal Insufficiency · United States | 1 | Completed | AN2 Therapeutics | Jun 10, 2022 | 40 |
| NCT04892641Healthy Volunteers · Australia | 1 | Completed | AN2 Therapeutics | Feb 26, 2022 | 51 |
| NCT01702350Community-Acquired Infections · Australia | 1 | Terminated | GlaxoSmithKline | Dec 8, 2011 | 24 |
| NCT01495065Community-Acquired Infections · United States | 1 | Terminated | GlaxoSmithKline | Feb 17, 2012 | 8 |
| NCT01475695Community-Acquired Infections · Netherlands | 1 | Completed | GlaxoSmithKline | May 19, 2011 | 6 |
| NCT01381562Infections · United States, Canada, Czechia and more | 2 | Terminated | GlaxoSmithKline | Mar 5, 2012 | 15 |
| NCT01381549Urinary Tract Infections · United States, Canada, France and more | 2 | Terminated | GlaxoSmithKline | Mar 6, 2012 | 20 |
| NCT01267968Community-Acquired Infections · United States | 1 | Completed | GlaxoSmithKline | Mar 16, 2011 | 25 |
| NCT01262885Bacterial Infections · Australia | 1 | Completed | GlaxoSmithKline | Aug 25, 2011 | 84 |
| NCT01015014Gram-Negative Bacterial Infections · Australia | 1 | Completed | Pfizer | May 13, 2010 | 64 |
How it is read
Names in the registry
- “Epetraborole”, 5 entries
- “GSK2251052”, 4 entries
- “AN3365”, 1 entry
- “Drug: GSK2251052”, 1 entry
- “14C GSK2251052”, 1 entry
Codes read as this program: GSK2251052.
Conditions, from the studies’ own filings
- Community-Acquired Infections, 4 studies
- Polycythemia Vera, 1 study
- Respiratory Tract Infections, 1 study
- Renal Insufficiency, 1 study
- Gram-Negative Bacterial Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.